Literature DB >> 15716518

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

N I Bohnen1, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, R A Koeppe, C C Meltzer, G Constantine, J G Davis, C A Mathis, S T Dekosky, R Y Moore.   

Abstract

OBJECTIVES: To determine in vivo cortical acetylcholinesterase (AChE) activity and cognitive effects in subjects with mild Alzheimer's disease (AD, n = 14) prior to and after 12 weeks of donepezil therapy.
METHODS: Cognitive and N-[(11)C]methyl-piperidin-4-yl propionate ([(11)C]PMP) AChE positron emission tomography (PET) assessments before and after donepezil therapy.
RESULTS: Analysis of the PET data revealed mean (temporal, parietal, and frontal) cortical donepezil induced AChE inhibition of 19.1% (SD 9.4%) (t = -7.9; p<0.0001). Enzyme inhibition was most robust in the anterior cingulate cortex (24.2% (6.9%), t = -14.1; p<0.0001). Donepezil induced cortical inhibition of AChE activity correlated with changes in the Stroop Color Word interference scores (R(2) = 0.59, p<0.01), but not with primary memory test scores. Analysis of the Stroop test data indicated that subjects with AChE inhibition greater than the median value (>22.2%) had improved scores on the Stroop Color Word Test compared with subjects with less inhibition who had stable to worsening scores (t = -2.7; p<0.05).
CONCLUSIONS: Donepezil induced inhibition of cortical AChE enzyme activity is modest in patients with mild AD. The degree of cortical enzyme inhibition correlates with changes in executive and attentional functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716518      PMCID: PMC1739536          DOI: 10.1136/jnnp.2004.038729

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  31 in total

1.  Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease.

Authors:  N Tanaka; K Fukushi; H Shinotoh; S Nagatsuka ; H Namba; M Iyo; A Aotsuka; T Ota; S Tanada; T Irie
Journal:  J Cereb Blood Flow Metab       Date:  2001-03       Impact factor: 6.200

2.  Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain.

Authors:  Marsel Mesulam; Angela Guillozet; Pamela Shaw; Bruce Quinn
Journal:  Neurobiol Dis       Date:  2002-02       Impact factor: 5.996

Review 3.  Cholinesterase inhibitors: A new class of psychotropic compounds.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

4.  Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain.

Authors:  R A Koeppe; K A Frey; S E Snyder; P Meyer; M R Kilbourn; D E Kuhl
Journal:  J Cereb Blood Flow Metab       Date:  1999-10       Impact factor: 6.200

5.  Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.

Authors:  D E Kuhl; S Minoshima; K A Frey; N L Foster; M R Kilbourn; R A Koeppe
Journal:  Ann Neurol       Date:  2000-09       Impact factor: 10.422

6.  Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.

Authors:  R T Staff; H G Gemmell; M F Shanks; A D Murray; A Venneri
Journal:  Nucl Med Commun       Date:  2000-01       Impact factor: 1.690

7.  Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.

Authors:  M S Mega; I D Dinov; L Lee; S M O'Connor; D M Masterman; B Wilen; F Mishkin; A W Toga; J L Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

8.  In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease.

Authors:  D E Kuhl; R A Koeppe; S Minoshima; S E Snyder; E P Ficaro; N L Foster; K A Frey; M R Kilbourn
Journal:  Neurology       Date:  1999-03-10       Impact factor: 9.910

9.  Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.

Authors:  H Shinotoh; A Aotsuka; K Fukushi; S Nagatsuka; N Tanaka; T Ota; S Tanada; T Irie
Journal:  Neurology       Date:  2001-02-13       Impact factor: 9.910

10.  PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor.

Authors:  B Bencherif; C J Endres; J L Musachio; A Villalobos; J Hilton; U Scheffel; R F Dannals; S Williams; J J Frost
Journal:  Synapse       Date:  2002-07       Impact factor: 2.562

View more
  56 in total

1.  Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction?

Authors:  Tamara G Fong; Sharon K Inouye; Weiying Dai; Daniel Z Press; David C Alsop
Journal:  Brain Imaging Behav       Date:  2011-03       Impact factor: 3.978

Review 2.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

3.  Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease.

Authors:  Maria Carmela Tartaglia; Bei Hu; Kala Mehta; John Neuhaus; Kristine Yaffe; Bruce L Miller; Adam Boxer
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Apr-Jun       Impact factor: 2.703

Review 4.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

5.  Rivastigmine for dementia associated with Parkinson's disease.

Authors:  John Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

6.  Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

Authors:  Pedro J Modrego; Miguel A Pina; Nicolás Fayed; Marcos Díaz
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment.

Authors:  Chitra Loganathan; Palvannan Thayumanavan
Journal:  Metab Brain Dis       Date:  2017-10-31       Impact factor: 3.584

8.  Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil.

Authors:  Kristin Huse Haug; Inger Lise Bogen; Harald Osmundsen; Ivar Walaas; Frode Fonnum
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

9.  Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M1 receptors.

Authors:  Lisa M Broad; Helen E Sanger; Adrian J Mogg; Ellen M Colvin; Ruud Zwart; David A Evans; Francesca Pasqui; Emanuele Sher; Graham N Wishart; Vanessa N Barth; Christian C Felder; Paul J Goldsmith
Journal:  Br J Pharmacol       Date:  2018-11-16       Impact factor: 8.739

10.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.